Camber Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $33M | Buy |
600,000
+100,000
| +20% | +$5.5M | 3.1% | 10 |
|
|
2025
Q1 | $35.3M | Buy |
500,000
+50,000
| +11% | +$3.53M | 1.26% | 14 |
|
|
2024
Q4 | $29.6M | Buy |
+450,000
| New | +$29.6M | 0.68% | 24 |
|
|
2024
Q3 | – | Sell |
-1,100,000
| Closed | -$90.6M | – | 35 |
|
|
2024
Q2 | $90.6M | Buy |
1,100,000
+850,000
| +340% | +$70M | 2.51% | 13 |
|
|
2024
Q1 | $21.8M | Buy |
+250,000
| New | +$21.8M | 0.54% | 26 |
|
|
2023
Q4 | – | Sell |
-300,000
| Closed | -$26.5M | – | 37 |
|
|
2023
Q3 | $26.5M | Buy |
+300,000
| New | +$26.5M | 0.87% | 26 |
|
|
2022
Q4 | – | Sell |
-800,000
| Closed | -$67.8M | – | 40 |
|
|
2022
Q3 | $67.8M | Sell |
800,000
-700,000
| -47% | -$59.3M | 2.08% | 17 |
|
|
2022
Q2 | $124M | Buy |
1,500,000
+200,000
| +15% | +$16.6M | 5.39% | 5 |
|
|
2022
Q1 | $100M | Buy |
1,300,000
+285,000
| +28% | +$22M | 3.63% | 13 |
|
|
2021
Q4 | $89.7M | Sell |
1,015,000
-135,000
| -12% | -$11.9M | 3.08% | 11 |
|
|
2021
Q3 | $88.9M | Buy |
+1,150,000
| New | +$88.9M | 2.74% | 12 |
|
|
2020
Q4 | – | Sell |
-400,000
| Closed | -$30.4M | – | 31 |
|
|
2020
Q3 | $30.4M | Buy |
+400,000
| New | +$30.4M | 1.61% | 22 |
|